Switzerland-based Roche's lung cancer drug Tecentriq (atezolizumab) has improved overall survival rate in a phase III IMpower110 study, it was reported yesterday.
The trial is assessing the product as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations (Wild-Type or WT).
The company's phase III trial achieved its primary endpoint in an interim analysis demonstrating that Tecentriq monotherapy had a statistically significant overall survival benefit in people with high PD-L1 expression (TC3/IC3-WT) compared against chemotherapy alone.
The firm will share the positive data with global health authorities such as the US Food and Drug Administration and European Medicines Agency to offer the new drug option to patients.
The product is a monoclonal antibody developed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. It will allow the activation of T cells by inhibiting PD-L1.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib